| 1402683-14-0

• CAS: 1402683-14-0
• 化学式: C₂₃H₁₇Cl₂N₅Ru
• 分子量: 535.397
• InChiKey: QEKFHBYZMPPJAF-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  [RuCl2(benzene)]2 、 来曲唑 以 乙醇 为溶剂， 反应 1.0h， 生成 、
  参考文献：
  名称：

  New Ruthenium(II)–Letrozole Complexes as Anticancer Therapeutics

  摘要：

  Novel ruthenium letrozole complexes have been prepared, and cell viability of two human cancer cell types (breast and glioblastoma) was determined. Some ruthenium compounds are known for their cytotoxicity to cancer cells, whereas letrozole is an aromatase inhibitor administered after surgery to post-menopausal women with hormonally responsive breast cancer. A significant in vitro activity was established for complex 5.Let against breast cancer MCF-7 cells and significantly lower activity against glioblastoma U251N cells. The activity of 5.Let was even higher than that of 4, a compound analogous to the well-known drug RAPTA-C. Results from the combination of 5.Let (or 4) with 3-methyladenine (3-MA) or with curcumin, respectively, revealed that the resultant cancer cell death likely involves 5.Let-induced autophagy.

  DOI：

  10.1021/jm301103y